Psychostimulants as cognitive enhancers – the evidence for the use and abuse of smart drugs
Poppy Goldsmith, Kirstie Anderson
Advances in Clinical Neuroscience & Rehabilitation · 2022
doi:10.47795/cuun2886 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
While modafinil is licensed to treat narcolepsy as a psychostimulant, there is widespread use as a “smart drug” in the young to help study and interest in older populations as a cognitive enhancer. This review considers both the evidence for benefit and potential for harm. If it is as effective as it seems, should we all be using it? Should neurologists recommend it, and should we worry if our patients are taking it? In this review the evidence base behind psychostimulants, in particular modafinil as a cognitive enhancer, is discussed.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.